Insider sales are immaterial in size and do not signal concern. Director Parham's sale without a plan is the only notable element, but the dollar amount is too small to be informative. Monitor next 10-Q for any change in insider selling patterns.
LH drugs
LH drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+5- T+0 · Nov 5 $363.30entry
- T+1 · 11d ago +0.90%α +0.59% · $366.57
- T+5 · 5d ago +2.48%α −0.81% · $372.32
- T+7 · todayOpen
- T+20 · in 17d Pending
- T+60 · in 3mo Pending
Price Chart
How similar events traded
Executive Summary
Two insiders at Labcorp sold shares in the week following strong Q3 earnings and raised guidance. Director Parham sold $389K open-market without a 10b5-1 plan, while EVP Vaughn sold $108K under a 10b5-1 plan. Total sales of $498K represent 0.0017% of market cap, a trivial amount.
Key Financial Metrics
Key Facts
- Director Parham sold 1,078 shares open-market on 2026-10-30 at $361.22, total $389K, no 10b5-1 plan
- EVP Vaughn sold 306 shares open-market on 2026-11-03 at $353.70, total $108K, under 10b5-1 plan
- Total open-market sales of $498K represent 0.0017% of Labcorp's $28.7B market cap
- Sales occurred 2-6 days after Q3 earnings beat and guidance raise
Financial Impact
Total insider sales of $498K, trivial relative to $28.7B market cap
Risk Factors
- Director Parham's sale without a 10b5-1 plan could be opportunistic, but the $389K amount is negligible for a $28.7B company
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-LH-1793883654935 |
Track record
29 reports on LH
5 of 5 bullish or bearish reports moved the stock their way by T+5. Best: +17.60% at T+60 after the Apr 30, 2026 report. 5 of 5 went positive at some point.
Filters
- Nov 12, 20264d ago Insider Cluster Neutral 2/10 Entry $372.32 Now $372.46 +0.04% settles Nov 19
- Nov 10, 20266d ago 144 Neutral 2/10 Entry $372.23 Now $372.46 +0.06% settles Nov 18
- Nov 5, 202611d ago Insider Cluster Neutral 2/10 Viewing Entry $363.30 to $372.32 Now $372.46 +2.52% ▲ +2.48% −0.81% vs SPY
- Nov 4, 202612d ago 144 Neutral 2/10 Entry $367.79 to $372.23 Now $372.46 +1.27% ▲ +1.21% +2.12% vs SPY
- Nov 4, 202612d ago 8-K Neutral 2/10 Entry $367.79 to $372.23 Now $372.46 +1.27% ▲ +1.21% +2.12% vs SPY
- Nov 3, 202613d ago 144 Neutral 2/10 Entry $353.92 to $370.88 Now $372.46 +5.24% ▲ +4.79% +5.38% vs SPY
- Oct 30, 202617d ago 144 Neutral 2/10 Entry $361.39 to $366.57 Now $372.46 +3.06% ▲ +1.43% +4.14% vs SPY
- Oct 28, 202619d ago 8-K Bullish 6/10 Entry $360.25 to $367.79 Now $372.46 +3.39% ▲ +2.09% +2.81% vs SPY
- Oct 26, 202621d ago Institutional Cluster Neutral 3/10 Entry $329.90 to $361.39 Now $372.46 +12.90% ▲ +9.55% +10.81% vs SPY
- Oct 21, 202626d ago 8-K Neutral 2/10 Entry $323.75 to $331.17 Now $372.46 +15.05% ▲ +2.29% +2.74% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers